Davidson Kempner Expects Thermo Fisher Scientific's Current Offer for QIAGEN N.V. to Fail

LONDON, July 28, 2020 /PRNewswire/ --

    1. Davidson Kempner European Partners, LLP is the sub-adviser to Davidson
       Kempner Capital Management LP which acts as the discretionary investment
       manager to various funds which represent 5.1% of the share capital of
       QIAGEN N.V. (the "Company")
    2. Davidson Kempner believes the standalone fair value for the Company to be
       EUR48-52 per share
    3. Davidson Kempner will not be tendering its shares and fully expects the
       current offer to fail
    4. Davidson Kempner has launched a website containing supporting information
       and evidence: https://unlockthevalueofqiagen.com/

For media enquiries:
Greenbrook
Andrew Honnor, Rob White, Fanni Bodri
Email: davidsonkempner@greenbrookpr.com
Tel: +44 (0) 20 7952-2000

View original content:http://www.prnewswire.com/news-releases/davidson-kempner-expects-thermo-fisher-scientifics-current-offer-for-qiagen-nv-to-fail-301101352.html

SOURCE Davidson Kempner